What is the Jubilant Pharmova PE ratio today?
Jubilant Pharmova's PE ratio is 42.5 at the 29 October 2026 close (₹946.00 a share): a market capitalisation of ₹14,947 crore divided by consolidated net profit of ₹352 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹399 crore) it is 37.5.
Is Jubilant Pharmova debt free?
No. Jubilant Pharmova had borrowings of ₹3,220 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.45. Its cash and current investments were ₹1,268 crore, so its net debt was ₹1,952 crore.
What is the Jubilant Pharmova debt to equity ratio?
Jubilant Pharmova's debt-to-equity ratio was 0.45 on 31 March 2026: borrowings of ₹3,220 crore against total equity of ₹7,096 crore. A year earlier, on 31 March 2025, it was 0.39.
What is the Jubilant Pharmova PB ratio (price to book value)?
Jubilant Pharmova's price-to-book (PB) ratio is 2.11 at the 29 October 2026 close: a market capitalisation of ₹14,947 crore divided by shareholders' equity (book value) of ₹7,093 crore on 31 March 2026. That is a book value of ₹448.91 per share against a share price of ₹946.00.
What is the Jubilant Pharmova net worth?
Jubilant Pharmova's net worth — shareholders' equity in its consolidated balance sheet — was ₹7,093 crore on 31 March 2026, up 13.4% from ₹6,255 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹14,947 crore at the 29 October 2026 close.
What is the Jubilant Pharmova ROE and ROCE?
In FY26, Jubilant Pharmova's return on equity (ROE) was 6.0% and its return on capital employed (ROCE) was 7.0%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 14.4% and ROCE 8.0%.
What is the Jubilant Pharmova market cap?
Jubilant Pharmova's market capitalisation was ₹14,947 crore at the 29 October 2026 close: 15.8 crore shares at ₹946.00 each.
What is the Jubilant Pharmova EPS?
Jubilant Pharmova's basic earnings per share (EPS) were ₹25.15 in FY26, against ₹52.99 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹22.23.
What is the Jubilant Pharmova dividend in 2026 and its record date?
In 2026, Jubilant Pharmova has declared one dividend: ₹5 with record date 24 July 2026.
What is the Jubilant Pharmova book value per share?
Jubilant Pharmova's book value per share was ₹448.91 on 31 March 2026: shareholders' equity of ₹7,093 crore divided by the 15.8 crore shares in issue, up 13.4% from ₹395.88 a year earlier. The share price at the 29 October 2026 close was ₹946.00.
What is the Jubilant Pharmova dividend yield?
Jubilant Pharmova's dividend yield is 0.53% at the 29 October 2026 close: dividends of ₹5 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹946.00. They were ₹5 on 24 July 2026.
What are the Jubilant Pharmova latest quarterly results?
Jubilant Pharmova's latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: consolidated net profit ₹56.5 crore, down 45.1% from ₹103 crore in Q1 FY26; revenue from operations ₹2,229 crore, up 17.3% year on year.
What is the Jubilant Pharmova promoter holding?
Promoters held 47.68% of Jubilant Pharmova on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Jubilant Pharmova free cash flow?
In FY26, Jubilant Pharmova generated ₹1,227 crore of cash from operations and spent ₹1,449 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹222 crore. In FY25 it was −₹43.5 crore.
What is the Jubilant Pharmova revenue and profit in FY26?
In FY26 (April 2025–March 2026), Jubilant Pharmova's consolidated net profit was ₹399 crore, down 52.5% from ₹839 crore in FY25, on revenue from operations of ₹8,280 crore (up 14.4%).
What is the Jubilant Pharmova shareholding pattern?
On 30 September 2026, Jubilant Pharmova's shares were held by promoters 47.68%, foreign portfolio investors (FII/FPI) 15.38%, domestic institutions (DII) 13.02% (including mutual funds at 9.42%) and retail and other non-institutional investors 23.38%. Over the year, FII holding was down 1.19 percentage points from 16.57% and DII holding was up 2.50 percentage points from 10.52%.
When are the Jubilant Pharmova next results?
Jubilant Pharmova has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
Jubilant Pharmova vs Gland Pharma: how do they compare?
In FY26, Jubilant Pharmova earned net profit of ₹399 crore on revenue of ₹8,280 crore, against ₹1,027 crore on ₹6,431 crore for Gland Pharma. Jubilant Pharmova's operating margin was 9.9% (Gland Pharma 18.8%) and its return on equity 6.0% (Gland Pharma 10.5%). At the 29 October 2026 close, Jubilant Pharmova's market capitalisation was ₹14,947 crore against ₹50,717 crore for Gland Pharma, and its PE ratio on FY26 profit 37.5 against 49.4.
How does Jubilant Pharmova compare with its peers?
On FY26 consolidated figures, against Gland Pharma, Piramal Pharma and Krishna Institute of Medical Sciences: Jubilant Pharmova's operating margin of 9.9% is the third highest of the four (Gland Pharma 18.8%, Piramal Pharma 1.0%, Krishna Institute of Medical Sciences 13.3%; peer average 11.0%); its return on equity of 6.0% is the third highest of the four (Gland Pharma 10.5%, Piramal Pharma −4.0%, Krishna Institute of Medical Sciences 11.0%; peer average 5.8%); its revenue growth over three years of 9.6% a year is the third highest of the four (Gland Pharma 21.1% a year, Piramal Pharma 7.8% a year, Krishna Institute of Medical Sciences 21.1% a year; peer average 16.7% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
